By Gilang Cahya 
Researchers from leading institutions, including the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK), have unveiled a significant discovery linking age-related genetic changes in blood cells to poorer prognoses in cancer patients. Their groundbreaking study, published in the esteemed New England Journal of Medicine, reveals that clonal haematopoiesis of indeterminate potential (CHIP) – a phenomenon characterized by the accumulation of mutations in blood stem cells, often associated with aging – can be found within cancerous tumors and is directly correlated with increased cancer relapse and mortality. This finding offers crucial insights into the complex interplay between aging, genetics, and cancer progression, with profound implications for understanding and potentially treating age-related diseases.
The Genesis of CHIP and its Unforeseen Link to Solid Tumors
The aging process is intrinsically linked to cellular changes, including the accumulation of genetic mutations. CHIP, a condition that arises when blood stem cells acquire these mutations over time, is influenced by both the natural passage of years and external environmental stressors. While CHIP has previously been identified as a risk factor for age-related disorders such as cardiovascular disease, its direct impact on the evolution and progression of solid tumors remained a significant area of inquiry.
This comprehensive study, a collaborative effort involving over 400 lung cancer patients from the Cancer Research UK funded TRACERx and PEACE studies, alongside data from 49,000 patients with various cancer types at MSK, sought to bridge this knowledge gap. The initial phase involved analyzing blood samples to identify patients with CHIP mutations. The subsequent correlation with clinical data yielded a striking observation: the presence of these mutations was associated with a reduced lifespan for patients, irrespective of their age at diagnosis or the stage of their cancer.
Unmasking Tumor-Infiltrating Clonal Haematopoiesis (TI-CH)
The researchers delved deeper, investigating whether the CHIP mutations identified in the blood were also present within the patients’ solid tumors, specifically lung tumors. This investigation revealed a critical distinction: the presence of CHIP mutations within the tumor microenvironment, termed tumor-infiltrating clonal haematopoiesis (TI-CH), was the true driver of worse patient outcomes. Approximately 42% of patients with CHIP exhibited these mutations within their lung tumors, indicating a direct infiltration of these mutated blood cells. It was this infiltration, rather than CHIP alone, that proved to be a significant predictor of increased cancer relapse and cancer-related death.
Further validation of this phenomenon came from the PEACE study, a retrospective analysis that examined post-mortem samples from patients who had succumbed to cancer. This study focused on metastatic sites, the areas where cancer has spread and is typically the cause of death. The findings from the PEACE study corroborated the earlier observations, revealing that metastatic tumors at these secondary sites frequently contained TI-CH mutations. This suggests that mutated blood cells not only infiltrate primary tumors but also contribute to the spread and lethality of the disease.
The Unequal Impact of Mutations: TET2 and Myeloid Cell Expansion
To elucidate the mechanisms by which TI-CH contributes to poor patient prognoses, the scientists meticulously examined the cellular composition of lung tumors. Their analysis uncovered a significant expansion of myeloid cells in patients with TI-CH. Myeloid cells, a crucial component of the immune system, play a multifaceted role within the tumor microenvironment. Unlike certain immune cells that are programmed to identify and attack cancer cells, myeloid cells are known to modulate inflammation and can, in some contexts, actively support tumor growth and dissemination.
The study also pinpointed specific genetic mutations that predispose these myeloid cells to infiltrate tumors. Mutations in the TET2 gene, a critical regulator of blood cell production, were found to be particularly prevalent. Across thousands of individuals analyzed, blood cells carrying TET2 mutations demonstrated a heightened propensity to infiltrate tumors. Further single-cell analysis of tumor samples from patients with TI-CH confirmed that TET2 mutations were predominantly found in myeloid cells, underscoring their specific role in this process.
In a significant experimental validation, researchers collaborated with experts in blood cancer and CHIP within a Crick laboratory led by Dominique Bonnet. They successfully generated organoids – miniature, lab-grown tumors – incorporating TET2-mutant myeloid cells. This controlled experiment demonstrated that these mutant myeloid cells actively remodeled the tumor microenvironment and accelerated the growth of the tumor organoids. This provides strong evidence for a causal link between TET2-mutant myeloid cell infiltration and aggressive tumor behavior.
Broadening the Scope: TI-CH Across Diverse Cancer Types
The research team, in partnership with colleagues at Memorial Sloan Kettering Cancer Center, extended their investigation to a much larger and more diverse dataset, encompassing over 49,000 patients with a wide spectrum of cancers. This extensive analysis confirmed that the presence of TI-CH served as an independent predictor of shorter survival across various cancer types.
However, the prevalence of CHIP and TI-CH varied significantly depending on the specific cancer. The study found these age-related mutations to be more frequently observed in cancers that are notoriously difficult to treat, including lung cancer, head and neck cancer, and pancreatic cancer. This observation suggests that the interplay between aging-related blood cell mutations and tumor biology might be a more significant factor in the aggressiveness and treatment resistance of certain cancers.
Implications for Future Cancer Research and Intervention
The findings from this comprehensive study carry substantial implications for the future of cancer research and clinical practice.
Understanding the Aging-Cancer Continuum
This research firmly establishes a biological link between the aging process, manifested through CHIP, and the progression of cancer. As the global population ages, the incidence of both age-related diseases and cancer is expected to rise. Understanding how cellular changes associated with aging, like CHIP, contribute to disease pathogenesis is paramount for developing effective preventative and therapeutic strategies for this growing demographic.
Novel Diagnostic and Prognostic Markers
The identification of TI-CH as a key indicator of poor prognosis opens avenues for developing novel diagnostic and prognostic tools. Detecting the presence of these infiltrating mutant blood cells within tumors could potentially allow clinicians to stratify patients based on their risk of relapse and mortality, enabling more personalized treatment approaches.
Therapeutic Targets and Intervention Strategies
The mechanistic insights gained, particularly regarding the role of TET2-mutant myeloid cells, could pave the way for targeted therapeutic interventions. Strategies aimed at inhibiting the infiltration of these cells, or modulating their pro-tumorigenic functions, could represent a new frontier in cancer treatment, especially for aggressive and treatment-resistant cancers. Furthermore, understanding the fundamental mechanisms by which aging cells influence cancer could lead to preventative measures against certain age-related cancers.
The Road Ahead: Confirmation and Mechanistic Detail
The researchers acknowledge that further work is necessary. The next critical steps involve definitively confirming that CHIP directly contributes to cancer outcomes and meticulously detailing the precise molecular mechanisms through which CHIP functionally influences the development of aggressive cancers. This ongoing research promises to deepen our understanding of this complex biological interplay.
Oriol Pich, a Postdoctoral Project Research Scientist at the Crick and a lead author on the study, emphasized the significance of their findings: "Our results show that blood cells carrying age-related mutations can infiltrate tumors and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer."
Charlie Swanton, Deputy Clinical Director at the Crick and Chief Clinician at Cancer Research UK, highlighted the novelty of the research: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk. As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers."
This pioneering work, supported by Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, among other funders, represents a significant leap forward in our comprehension of how the aging process influences cancer. It offers a beacon of hope for developing more effective strategies to combat this pervasive disease, particularly in an increasingly aging global population. The collaborative nature of this research, spanning multiple institutions and disciplines, underscores the power of collective scientific endeavor in tackling complex health challenges.
